10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

or

☐     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number 000-54949

BioAdaptives Inc.

(Exact name of registrant as specified in its charter)

 

Delaware	46-2592228
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
2620 Regatta Drive, Suite 102, Las Vegas, NV	89128
(Address of principal executive offices)	(Zip Code)

 

(702) 659-8829

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES     ☐ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ YES     ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES     ☒ NO

Large accelerated filer	☐	Accelerated filer	☐
Non-Accelerated filer	☒	Smaller reporting Company	☒
Emerging Growth Company	☐

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ☒ YES     ☐ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

18,576,379 common shares issued and outstanding as of May 29, 2020

Form 10-Q

Table of Contents

PART I – FINANICAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19
Item 4.	Controls and Procedures	19
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosure	21
Item 5.	Other Information	21
Item 6.	Exhibits	22
	Signatures	23

2

Statement Regarding COVID-19-Related Filing Delay

BioAdaptives, Inc. has relied on the U.S. Securities and Exchange Commission’s March 25, 2020, Order [Rel. No. No. 34-88465] to postpone filing this Current Report for the period ended March 31, 2020. The reasons for our postponement are set out fully in our May 11, 2020, Form 8-K, which is incorporated here by reference. In sum, we conduct our business operations from Law Vegas, Nevada, which has been subject to shut-down and stay-at-home orders during the period allocated to preparation of this report. Furthermore, our senior officers responsible for preparation of the financial statements and other reports contained herein reside out-of-state and have been subject to various travel restrictions.

3

PART I - FINANICAL INFORMATION

Item 1. Financial Statements

PART I - FINANICAL INFORMATION

BIOADAPTIVES, INC.

CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2020			2019
ASSETS
Current Assets:
Cash	$	11,649		$	12,313
Accounts receivable		179			-
Marketable securities		412			772
Inventory		14,469			11,128
Total Current Assets		26,709			24,213
TOTAL ASSETS	$	26,709		$	24,213
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		48,503			29,954
Derivative liabilities		509,395			464,024
Current portion of convertible notes - net of discount of $33,981 and $71,607		393,519			312,893
Notes Payable		9,711			7,218
Note payable - related party		50,000			50,000
Total Current Liabilities		1,011,128			864,089
Total Liabilities		1,011,128			864,089
Stockholders' Deficit:
Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)		-			-
Series A Preferred Stock 4,000,000 shares designated; none issued and outstanding
Common stock ($.0001 par value, 200,000,000 shares authorized; 18,576,379 and 18,096,169 shares issued and outstanding, and 1,035,304 and 275,502 issuable, respectively)		1,961			1,894
Additional paid-in capital		4,010,459			3,917,147
Accumulated deficit		(4,996,839	)		(4,758,917	)
Total Stockholders' Deficit		(984,419	)		(839,876	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	26,709		$	24,213

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three months ended
	March 31,
	2020			2019
Revenues	$	4,655		$	1,532
Cost of revenue		1,362			340
Gross Profit		3,293			1,192
Operating Expenses
General and administrative		39,432			9,767
Professional fees		9,090			35,900
Stock based compensation		93,379			21,000
Total Operating Expenses		141,901			66,667
Other Income (Expense)
Unrealized loss on marketable securities		(360	)		(1,544	)
Interest expense		(53,583	)		(48,981	)
Change in fair value of derivative liabilities		(45,371	)		208,445
Total Other Income (Expense)		(99,314	)		157,920
Loss before income taxes		(237,922	)		92,445
Net loss	$	(237,922	)	$	92,445
Net Loss Per Common Share:
Basic and Diluted	$	(0.01	)	$	0.01
Diluted	$	(0.01	)	$	(0.00	)
Weighted Average Number of Common Shares Outstanding:
Basic		18,938,769			18,423,893
Diluted		18,938,769			22,620,925

The accompanying notes are an integral part of these unaudited consolidated financial statements.

5

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

	Series A Preferred stock				Common stock				paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total
Balance, December 31, 2019		-	$	-		18,938,769	$	1,894	$	3,917,147	$	(4,758,917	)	$	(839,876	)
Common stock issued for service		-		-		400,000		40		47,075		-			47,115
Common stock issued for service - related party		-		-		272,914		27		35,973		-			36,000
Stock based compensation		-		-		-		-		10,264		-			10,264
Net loss for the period		-		-		-		-		-		(237,922	)		(237,922	)
Balance, March 31, 2020		-	$	-		19,611,683	$	1,961	$	4,010,459	$	(4,996,839	)	$	(984,419	)

									Additional
	Series A Preferred stock				Common stock				paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total
Balance, December 31, 2018		-	$	-		18,371,671	$	1,837	$	3,824,412	$	(4,519,990	)	$	(693,741	)
Common stock issued for service - related party		-		-		144,713		15		20,985		-			21,000
Net loss for the period		-		-		-		-		-		92,445			92,445
Balance, March 31, 2019		-	$	-		18,516,384	$	1,852	$	3,845,397	$	(4,427,545	)	$	(580,296	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three months ended
	March 31,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(237,922	)	$	92,445
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		47,115			-
Stock-based compensation - related party		46,264			21,000
Change in fair value of derivative liabilities		45,371			(208,445	)
Amortization of debt discount		40,626			38,763
Unrealized loss on investments in marketable securities		360			1,544
Changes in operating assets and liabilities:
Accounts receivable		(179	)		-
Inventory		(3,341	)		40,078
Accounts payable and accrued liabilities		19,392			(32,281	)
Net Cash Used in Operating Activities		(42,314	)		(46,896	)
CASH FLOWS FROM INVESTING ACTIVITIES
Sales of assets		-			-
Net cash Provided by Investing Activities		-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable		9,800			10,000
Repayments of notes payable		(8,150	)		-
Proceeds from convertible notes		40,000			-
Net Cash Provided by Financing Activities		41,650			10,000
Net change in cash		(664	)		(36,896	)
Cash at beginning of period		12,313			56,215
Cash at end of period	$	11,649		$	19,319
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	8,930

The accompanying notes are an integral part of these unaudited consolidated financial statements.

7

BioAdaptives, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

BioAdaptives, Inc. (formerly known as APEX 8 Inc.) (“BioAdaptives”,” Company”) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products and strategies that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages. Our base of intellectual property and products, which are patent pending solutions in the form of devices and nutraceuticals, are designed to aid in cognition, focus, fatigue reduction, increased testosterone, improved overall emotional and physical wellness, healing, and anti-aging.

The Company’s strategy is to develop a position as a leader in supplying science-based quality nutraceutical products to an aging population within developed countries such as the United States, Canada, APAC countries, such as China, Japan, Korea, Singapore, Taiwan, Australia and New Zealand, as well as both Western and Eastern Europe, while continuing to create new innovative, health inspired products to start generating growth in sales and profitability. Some of the products have proven to be as effective or even more effective on horses and dogs than on humans and this has caused the Company to expand the target market to include dogs and horses.

Since 2014, BioAdaptives®, has been engaged in the research of primitive cells, including stem cells and their derivatives and natural ingredients which may encourage its proliferation. Such studies were conducted both on human and animals, in particular, canine and equine. The results have been encouraging. More in depth studies on this and other wellness aspects such as anti-aging and sports performance are scheduled.

On May 22, 2019, the Company moved its corporate office to 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128, but maintained fulfillment facilities at 4385 Cameron Street, Suite B, Las Vegas, NV 89103.

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10, have been omitted.

Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

8

Earnings (loss) per share

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.

Financial Instruments and Fair Value Measurements

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level at March 31, 2020 and December 31, 2019, measured at fair value on a recurring basis:

Fair Value Measurements as of March 31, 2020 Using:

	Total Carrying Value as of		Quoted Market Prices in Active		Significant Other Observable		Significant Unobservable
	March 31, 2020		Markets (Level 1)		Inputs (Level 2)		Inputs (Level 3)
Assets:
Equity Securities	$	412	$	412	$	-	$	-
Liabilities
Derivative liabilities	$	509,395	$	-	$	-	$	509,395

Fair Value Measurements as of December 31, 2019 Using:

	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	772	$	772	$	-	$	-
Liabilities
Derivative liabilities	$	464,024		-		-		464,024

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

9

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $4,996,839 as of March 31, 2020. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. MARKETABLE SECURITIES

Equity securities at March 31, 2020 and December 31, 2019, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $412 and $772, respectively.

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at March 31, 2020 and December 31, 2019 consists of the following.

	March 31,		December 31,
	2020		2019
Accounts payable	$	164	$	1,297
Credit card		22,763		20,214
Accrued interest		14,570		2,457
Accrued liabilities		11,006		5,986
	$	48,503	$	29,954

6. NOTE PAYABLE

During the three months ended March 31, 2020, the Company issued additional notes payable of $9,800 to a third party. The term is 6 months. During the three months ended March 31, 2020, the Company recognized interest expense of $589 and repaid $8,150. As of March 31, 2020 and December 31, 2019, the Company owed note payable of $9,711 and $7,218, respectively.

7. CONVERTIBLE NOTES

Convertible notes at March 31, 2020 and December 31, 2019 consists of the following:

	March 31,			December 31,
	2020			2019
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2019		73,500			73,500
Convertible Notes - issued fiscal year 2019		43,000			-
Total convertible notes payable		427,500			384,500
Less: Unamortized debt discount		(33,981	)		(71,607	)
Total convertible notes		393,519			312,893
Less: current portion of convertible notes		393,519			312,893
Long-term convertible notes	$	-		$	-

10

For the three months ended March 31, 2020 and 2018, the interest expense on convertible notes was $11,870 and $10,215, respectively. As of March 31, 2020, and December 31, 2019, the accrued interest was $13,261 and $1,391, respectively.

The Company recognized amortization expense related to the debt discount of $40,626 and $38,763 for the three months ended March 31, 2020 and 2019, respectively, which is included in interest expense in the statements of operation.

Convertible Notes – Issued during the year ended December 31, 2018

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of convertible notes are summarized as follows:

· Term two years;

· Annual interest rates 12%;

· Convertible at the option of the holders at any time

· Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes – Issued during the year ended December 31, 2019

During the year ended December 31, 2019, the Company issued a total principal amount of $73,500 in convertible notes for cash proceeds of $67,000. The terms of convertible notes are summarized as follows:

· Term one year;

· Annual interest rates 10%;

· Convertible at 180 days from issuance

· Conversion prices are 58 - 61% multiplied by the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes – Issued during the three months ended March 31, 2020

During the three months ended March 31, 2020, the Company issued a total principal amount of $43,000 in convertible note for cash proceeds of $40,000. The terms of convertible note are summarized as follows:

· Term one year;

· Annual interest rates 10%;

· Convertible at 180 days from issuance

· Conversion prices are 61% multiplied by the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

8. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

11

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of March 31, 2020. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

For the three months ended March 31, 2020 and year ended December 31, 2019, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Three months ended			Year ended
	March 31,			December 31,
	2020			2019
Expected term	0.01- 0.42 years			0.22 - 1.43 years
Expected average volatility	226% - 317		%	229% - 320		%
Expected dividend yield		-			-
Risk-free interest rate	0.05% - 0.15		%	1.55% - 2.40		%

The following table summarizes the changes in the derivative liabilities during the three months ended March 31, 2020.

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - December 31, 2019	$	464,024
Gain on change in fair value of the derivative		45,371
Balance - March 31, 2020	$	509,395

The aggregate (gain) loss on derivatives during the three months ended March 31, 2020 and 2019 was as follows;

	Three months ended
	March 31,
	2020		2019
(Gain) loss on change in fair value of the derivative liabilities	$	45,371	$	(208,445	)

9. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of March 31, 2020, and December 31, 2019, no shares of preferred stock had been issued.

Series A Preferred Stock

On February 6, 2020, the Company established its Series A Preferred Stock, par value .0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock (the “Shares”).

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

As of March 31, 2020, no shares of Series A Preferred Stock had been issued.

12

Common Stock

On February 6, 2020, the Company’s board and a majority of its shareholders approved an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of its common stock, par value .0001, from 100,000,000 shares to 200,000,000 shares.

During the three months ended March 31, 2020, the Company recorded 272,914 common stock issuable valued at $36,000 based on an employment agreement – related party transaction.

During the three months ended March 31, 2020, the Company recorded 400,000 common stock issuable valued at $47,115 for services.

As of March 31, 2020, and December 31, 2019, there were 19,611,683 and 18,938,769 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of March 31, 2020 and December 31, 2019, there were 1,105,514 shares and 832,600 shares of the Company’s common stock issuable, respectively.

Warrant

During the year ended December 31, 2018, the Company entered into an agreement with consultant to provide the Company with consulting services in exchange for 2-year warrant to purchase 200,000 shares of common stock with an exercise price of $0.1 per share. The Company recognized a warrant expense of $52,365, as stock-based compensation and additional paid-in capital. The Company determined that the warrants qualify for derivative accounting as a result of the related issuance of the convertible note on in April 2018, which led to no explicit limit to the number of shares to be delivered upon future settlement of the conversion options (see Note 8).

During the three months ended March 31, 2020, all warrant to purchase 200,000 shares of common stock were expired.

10. RELATED PARTY TRANSACTIONS

Notes payable – related party

During the year ended December 31, 2019, the Company issued a total principal amount of $50,000 notes to the company owned by our CEO. The note is a 4% interest bearing promissory note that the term is 1 year.

As of March 31, 2020 and December 31, 2019, the Company recorded notes payable – related party of $50,000 and $50,000 and accrued interest of $1,309 and $809, respectively.

Employee agreements

In June 2018, the Company originally entered into an employment agreement with Dr. Edwards E. Jacobs, Jr.,our CEO. A base compensation is $10,000 monthly and 100,000 shares of common stock valued at $27,500. In October 2018, the agreement was amended to a base compensation is $7,000 in cash or equivalent in common stock. During the three months ended March 31, 2020, the Company recorded Stock based compensation of $21,000 (See Note 9).

In August 2019, the Company entered into an employment agreement with Robert W. Ellis, our president. A base compensation is $5,000 in cash per monthly and 250,000 shares to be issued on August 31, 2020 valued at $26,375. During year ended December 31, 2019, the Company recorded Stock based compensation of $6,594. As of March 31, 2020 and December 31, 2019, the Company recorded accrued liability of $10,000 and $5,000, respectively.

In September 2019, the Company entered into an employment agreement with Ronald Lambrecht, our Chief Financial Officer. A base compensation is $5,000 equivalent in common stock monthly and 100,000 shares to be issued on September 30, 2020 valued at $11,010. The service will be provided from January 2, 2020. During the three months ended March 31, 2020, the Company recorded Stock based compensation of $18,670.

13

11. EARNING (LOSS) PER SHARE

The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations.

	Three months ended
	March 31,
	2020			2019
Numerator:
Net Income (Loss)	$	(237,922	)	$	92,445
Gain on change in fair value of derivatives		-			(208,445	)
Interest on convertible debt		-			10,215
Net Income (Loss) - diluted	$	(237,922	)	$	(105,785	)
Denominator:
Weighted-average shares of common stock		18,938,769			18,423,893
Dilutive effect of convertible instruments		-			4,134,404
Dilutive effect of outstanding warrants		-			62,628
Diluted weighted-average of common stock		18,938,769			22,620,925
Net Income (Loss) Per Common Share:
Basic:	$	(0.01	)	$	0.01
Diluted:	$	(0.01	)	$	(0.00	)

For the periods ended March 31, 2020, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

For the periods ended March 31, 2019, diluted earnings per share is calculated using net income available to common stockholders divided by the diluted weighted average number of common shares outstanding during each period determined using the treasury stock method and the if-converted method.

12. SUBSEQUENT EVENT

The Company has developed and is marketing PrimaLungs™, an enhanced formulation of nutraceuticals promoting overall health and wellness through support of pulmonary immune systems. PrimaLungs™ is packaged with PrimaCell® and PluriPain™ in the Immune Wellness Health Defense Package, which contains a 30-day supply of each compound. Additional information can be found at www.primalung.com and www.Pluripain.com.

The Company has commenced a marketing program to identify internet influencers and other notables in the TCM, Ayurvedic and animal health and wellness fields for affiliate marketing purposes. To-date, we have entered into two affiliate marketing agreements.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our”, “Company” and "BioAdaptives" mean BioAdaptives Inc., unless otherwise indicated.

1. OUR BUSINESS

Overview

BioAdaptives, Inc is a research, development, and educational company. We manufacture and distribute natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on pain relief, immune support, and anti-aging properties. These products include dietary supplements and specialty food items. These products are designed to aid memory, cognition, and focus; assist in sleep and fatigue reduction through increased mitochondrial energy; provide pain relief and healing; and generally, improve overall emotional and physical wellness. The science behind our products has also proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance. Our current product lines include PrimiCell^®, a primitive cell activator, PrimiLungs™, a lung immune defense product and PluriPain™, a fast-acting, long-lasting, all-natural pain relief management nutraceutical for humans. The Company also provides a cell activation line for dogs and horses, Canine Regen® and Equine Regen®, both based on our PrimiCell^® formulations. Additional products for sleep, mitochondrial energy, cognitive focus, and gut health, as well as a cosmeceutical duo for anti-aging for humans, and various enhancement and pain relief products for animals are presently being readied for introduction during 2020.

Market and Marketing

We market our science-based, quality nutraceuticals to a broad base of the population in the U.S., and are exploring marketing prospects in Asia, the Middle East, and Europe. The Company’s current target markets also include equine and canine companion animals and equine competitors in the U.S. and the Middle East.

15

We intend to create market share in our target demographic by (i) emphasizing the benefits of our proprietary algal based-all natural, stimulant free, non-GMO ingredients that combine with proven Traditional Chinese Medicine and Ayurvedic herbs into science-based formulations, (ii) creating additional products in response to market demand and testing, and (iii) utilizing our marketing operation to act as its sales and distribution arm to seek additional channels for sales coverage. While we do not pay for placement or mentions, the Company has entered into affiliate marketing agreements with internet influencers and other notables in TCM and Ayurvedic health and wellness fields to directly market our products for commissions. We believe the exposure from multiple credible sources in these disciplines will help our products gain recognition and directly promote sales.

The Company also plans to capitalize on the significant opportunities for consolidation available in the nutraceutical industry. The Company anticipates seeking acquisitions that serve to increase the number of the Company's product brands, broaden its product offering or facilitate entry into complementary distribution channels.

We are associated with leading veterinarians and equine competitors for both research and marketing purposes. In 2019, the Company formed the Livestock Impact™ Division, specifically for a line of “All-In-One”™ supplement feeds for show animals and companion animals, assisting the different facets of their wellness health, under Bruce Colclasure a NCHA champion who owns and operates the Flying C Bar Ranch, the breeder and trainer of over 80 NHCA champion cutting horses, as Division President. Colclasure, in the last five years, uses and endorses our EquineRegen® and EquineRegen^® Plus products and provides valuable feedback and testimonials regarding its function. The Company has also appointed Flying C bar Range Therapy, under Denise Colclasure as its marketing agent for LiveStock Impact™. Ms Colclasure, a respected and well-known personality in the equine and livestock industry, will be responsible for marketing the LiveStock Impact™ line of products at livestock events, equine shows, as well as to other breeders, trainers, stable operators, livestock owners and veterinarians. The Division also offers an Ambassadors’ program.

The Company believes that the population growth in the seasoned and geriatric demographic cohort presents a unique opportunity. The World Health Organization has stated that the 60 years and over population segment will more than double from 11% to over 22% between 2000 and 2050, with the absolute number of people aged 60 and over expected to increase to 2 billion within the same period. The Company also recognizes the rising buying power and interests of the Millennials in wellness products and their choice of communication medium being social media and internet. It intends to establish a major focus to capture the anticipated growth in this sector.

The Company also believes that international sales represent a significant future growth opportunity as aging population growth outside North America exceeds 1 billion people. The Company plans to aggressively pursue international sales by adding additional salespeople within its marketing effort, developing a network in high-growth APAC regions, and continuing its efforts to register products and trademarks in attractive foreign markets.

Manufacturing

All of the Company’s products are considered dietary supplements, feed supplements or natural foods, and we carefully avoid making health, drug or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all botanical or algal-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices or operate NSF-certified (or equivalent) facilities.

We utilize pharmaceutical grade contract manufacturers to assemble and package our products subject to our inspection and approval. Fulfillment of retail internet and direct-to-reseller orders are conducted from our warehouse facilities. BioAdaptives actively investigates new products, techniques and novel applications of existing products or technology in our research. The Company’s research work has centered on the development of all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation.

2. RESULTS OF OPERATIONS

Three Months Ended March 31, 2020 and 2019

We had a net loss of $237922 for the three-month period ended March 31, 2020, which was net loss of $330,367 more than for the three-month period ended March 31, 2019, which net income was $92,445. The change in our results over the two periods is primarily due to stock-based compensation, promotional expenses, and the change in fair value of derivative liabilities.

16

The following table summarizes key items of comparison and their related increase (decrease) for the three-month periods ended March 31, 2020 and 2019:

	2020			2019		Changes
Revenue		4,655			1,532		3,123
Cost of Sales		1,362			340		1,022
Operation Expenses		141,901			66,667		75,234
Other income (expenses)		(99,314	)		157,920		(257,234	)
Net Income (loss)		(237,922	)		92,445		(330,367	)

Revenue

Our revenues have been derived entirely from product sales.

Cost of Sales

Our cost of sales is primarily derived from contract manufacturing expenses and shipping and handling expenses related to customer fulfillment. We also expense small amounts for marketing expenses, which includes the cost of samples or products provided for promotional purposes and website content development.

Operation Expenses

Our general, administrative and professional fees are largely attributable to office, rent, advertising, consultants and transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company as well as stock-based compensation for officers, directors and consultants.

Other Income (Expense)

The Company recorded interest expense of $53,583and $48,981for the three months ended March 31, 2020 and March 31,2019.

Net Loss

As a result of our operating expenses the Company reported a net loss of $$237, 922 and an income of $92,445 for the three months ended March 31, 2020 and 2019.

Comprehensive Income (Loss)

The Company reported an unrealized loss on marketable securities of $360 and $1,544 for the three months ended March 31, 2020 and 2019.

Liquidity and Capital Resources

Our balance sheet as of March 31, 2020 reflects current assets of $26,709. We had cash in the amount of $11,649 and working capital deficiency in the amount of $984,419 as of March 31, 2020. We currently meet cash requirements by infusions of by issuance of notes to finance partners. Most of these notes have conversion features that require accounting for derivative liabilities.

17

 

Working Capital (Deficiency)	March 31,			December 31,
	2020			2019			Change
Current Assets		26,709			24,213			2,496
Current Liabilities		1,011,128			864,089			147,039
Working Capital (Deficiency)		(984,419	)		(839,976	)		(144,543	)

Cash Flows
	Three Months Ended March 31,
	2020			2019			Change
Cash provided by (used in) Operating Activities		(42,314	)		(46,896	)		4,582
Cash provided in Investing Activities		-			-			-
Cash provided by (used in) Financing Activities		41,650			10,000			31,650
Net Increase (Decrease) In Cash During Period		(664	)		(36,896	)		36.232

 

Net cash used by operating activities during the three months ended March 31, 2020 was $42,314 a(n) decrease/increase of $4,582 from the $46,896 net cash used in operating activities during the three months ended March 31, 2019.

Cash Flows from Financing Activities

Net cash provided by financing activities during the three months ended March 31, 2020 was $41.650 a(n) decrease/increase of $31,650 from the $10,000 net cash provided in financing activities during the three months ended March 31, 2020.

As of March 31, 2020, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Going Concern

At March 31, 2020, we had $11,649 of cash on-hand and an accumulated deficit of $984,419, and as noted throughout this report and our financial statements and notes thereto, our independent auditors have expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2019. We anticipate incurring significant losses in the future. We do not have an established source of revenue sufficient to cover our operating costs. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means. If we are unable to reverse our losses, we will have to discontinue operations.

The financial statements included in this quarterly report have been prepared assuming that we will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business.

18

Management's plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating of revenue through our business. However, even if we do raise sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively a that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Recent Accounting Pronouncements

The Company has evaluated recent pronouncements through Accounting Standards Updates ("ASU") and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, March 31, 2020. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below.

19

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of June 30, 2016, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment. and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both USGAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2019: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There was no change in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

20

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We know of no pending legal proceedings to which we are a party which are material or potentially material, either individually or in the aggregate. We are from time to time, during the normal course of our business operations, subject to various litigation claims and legal disputes. We do not believe that the ultimate disposition of any of these matters will have a material adverse effect on our consolidated financial position, results of operations or liquidity.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Co Vid-19 Pandemic Impact and Risk

At this time, it is not possible to fully assess the impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals, if required; (iv) delay, limit or preclude the Company from securing manufacturing sites, partnerships or marketing agreements; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to execute on its business plan.

The Company’s priority and commitment is to the health and security of its team members, their families, and its partners through this unprecedented event.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

21

Item 6. Exhibits

31.1	Section 302 Certification by the Principal Executive Officer
31.2	Section 302 Certification by the Principal Financial Officer
32.1	Section 906 Certification by the Principal Executive Officer
32.2	Section 906 Certification by the Principal Financial Officer

22

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioAdaptives Inc.
	(Registrant)
Dated: June 10, 2020		/s/ Edward E. Jacobs, Jr
		Edward E. Jacobs, Jr
		Chief Executive Officer,
		(Principal Executive Officer )
		/s/ Robert W. Ellis
		Robert W. Ellis
		President, Chief Financial Officer,
		(Principal Financial Officer)

23

EX-31.1

EXHIBIT 31.1

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, Edward E. Jacobs, Jr, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: June 10, 2020	By:	/s/Edward E. Jacobs, Jr
		Edward E. Jacobs, Jr
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, Robert W Ellis, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: June 10, 2020	By:	/s/Robert W Ellis
		Robert W Ellis
		President and Chief Financial Officer
		(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Edward E. Jacobs, Jr, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Edward E. Jacobs, Jr and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: June 10, 2020	By:	/s/ Edward E. Jacobs, Jr
		Edward E. Jacobs, Jr
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2

EXHIBIT 32.2

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert W Ellis, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Robert W. Ellis and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: June 10, 2020	By:	/s/ Robert W. Ellis
		Robert W. Ellis
		President and Chief Financial Officer
		(Principal Accounting Officer)

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 29, 2020
Document And Entity Information
Entity Registrant Name	BIOADAPTIVES, INC.
Entity Central Index Key	0001575142
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Common Stock Shares Outstanding		18,576,379
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes